-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Opaganib in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Opaganib in Solid Tumor Drug Details: Opaganib (ABC-294640) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Tofacitinib Citrate in Systemic Idiopathic Juvenile Arthritis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Tofacitinib Citrate in Systemic Idiopathic Juvenile Arthritis Drug Details: Tofacitinib (Xeljanz, Jaquinus) is an immunosuppressant....
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Tofacitinib Citrate in Chronic Granulomatous Disease
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Tofacitinib Citrate in Chronic Granulomatous DiseaseDrug Details: Tofacitinib (Xeljanz, Jaquinus) is an immunosuppressant. It is formulated...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Tofacitinib Citrate in Hidradenitis Suppurativa
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Tofacitinib Citrate in Hidradenitis Suppurativa Drug Details: Tofacitinib (Xeljanz, Jaquinus) is an immunosuppressant. It is...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ACT-777991 in Type 1 Diabetes (Juvenile Diabetes)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ACT-777991 in Type 1 Diabetes (Juvenile Diabetes) Drug Details: ACT-777991 is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – DS-1211 in Pseudoxanthoma Elasticum (PXE or Gronblad Strandberg Syndrome)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.DS-1211 in Pseudoxanthoma Elasticum (PXE or Gronblad Strandberg Syndrome)Drug Details:DS-1211 is under development for the prevention...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – REGN-9933 in Venous Thromboembolism
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. REGN-9933 in Venous Thromboembolism Drug Details: REGN-9933 is under development for the prevention of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Prademagene Zamikeracel in Epidermolysis Bullosa
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Prademagene Zamikeracel in Epidermolysis Bullosa Drug Details: Prademagene zamikeracel (EB-101) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Everolimus in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Everolimus in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Drug Details: Everolimus (Afinitor, Votubia, RAD001)...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Everolimus in Myelodysplastic Syndrome
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Everolimus in Myelodysplastic Syndrome Drug Details: Everolimus (Afinitor, Votubia, RAD001) is an ester of the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Everolimus in Ependymoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Everolimus in Ependymoma Drug Details: Everolimus (Afinitor, Votubia, RAD001) is an ester of the macrocytic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Everolimus in Follicular Thyroid Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Everolimus in Follicular Thyroid Cancer Drug Details: Everolimus (Afinitor, Votubia, RAD001) is an ester of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Everolimus in Papillary Thyroid Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Everolimus in Papillary Thyroid Cancer Drug Details: Everolimus (Afinitor, Votubia, RAD001) is an ester of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Everolimus in Metastatic Transitional (Urothelial) Tract Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Everolimus in Metastatic Transitional (Urothelial) Tract Cancer Drug Details: Everolimus (Afinitor, Votubia, RAD001) is an...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Everolimus in High-Grade Glioma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Everolimus in High-Grade Glioma Drug Details: Everolimus (Afinitor, Votubia, RAD001) is an ester of the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Everolimus in Low-Grade Glioma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Everolimus in Low-Grade Glioma Drug Details: Everolimus (Afinitor, Votubia, RAD001) is an ester of the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Everolimus in Pediatric Diffuse Intrinsic Pontine Glioma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Everolimus in Pediatric Diffuse Intrinsic Pontine Glioma Drug Details: Everolimus (Afinitor, Votubia, RAD001) is an...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Everolimus in Malignant Glioma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Everolimus in Malignant Glioma Drug Details: Everolimus (Afinitor, Votubia, RAD001) is an ester of the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Everolimus in Medullary Thyroid Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Everolimus in Medullary Thyroid Cancer Drug Details: Everolimus (Afinitor, Votubia, RAD001) is an ester of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – JTE-451 in Plaque Psoriasis (Psoriasis Vulgaris)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.JTE-451 in Plaque Psoriasis (Psoriasis Vulgaris) Drug Details:JTE-451 is under development for the treatment of autoimmune...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.